15 results about "Fibril formation" patented technology

The present invention relates to a cell-penetrating peptide and its derivatives to inhibit α-synuclein fibrillation. The present invention specifically relates to a peptide-based inhibitor of Parkinson's Disease. The present invention discloses the identification of the peptides permeable to blood brain barrier for inhibition. α-synuclein fibril formation is observed in the presence of peptides as indicated by SEQ. ID-7, SEQ. ID-8 wherein the SEQ. ID-7, SEQ. ID-8 are truncated versions of SEQ. ID-4 having the homology of 83% and 75% respectively. It provides a peptide having an amino acid sequence of Formula 1. The present invention also provides a pharmaceutical composition comprising a peptide of Formula 1 along with the pharmaceutically acceptable excipient(s) having inhibitory activity against β-sheet polymerisation of amyloidogenic proteins. The analysis showed that peptides corresponding to SEQ. ID-7, SEQ. ID-8 are better inhibitors than SEQ. ID-4 against α-synuclein fibrillation.

The porous membrane contains, as a main component, a thermoplastic resin having a melting point of 180-300 DEG C inclusive, and has a tortoise-shell-like structure comprising a plurality of nodes and a plurality of fibrils. Alternatively, the porous film contains, as the main component, a thermoplastic resin having a melting point of 180-300 DEG C inclusive, and the compression ratio of the porous film in the thickness direction when a pressure of 2.5 N / mm2 is applied is 20% or less. The thermoplastic resin contains, for example, a polymethylpentene resin. When the cross-section of the porous film is observed, a plurality of nodes are included, for example, in the thickness direction.

A method is provided for making a protein blocking assembly that is formed by reversibly linking a therapeutic protein to a crosslinking material. The protein blocking assembly contains a chemical structure, which is formed between the multiple bonds between the protein and the crosslinking material, that prevents the interaction of the protein blocking assembly with a second protein due to steric and / or static interference. Furthermore, administration methodologies of administering the protein blocking assembly to a subject are provided, where the protein is cleaved from the protein blocking assembly during or after administration.

To provide a flexible artificial blood vessel and an artificial blood vessel manufacturing method.SOLUTION: An artificial blood vessel VE is composed of stretched polytetrafluoroethylene having nodes and fibrils formed between the nodes. In an axial direction D1 of the artificial blood vessel VE, high-density areas R1 in which the nodes and the fibrils are compressed and dense in the axial direction D1 and low-density areas R2 in which the nodes and the fibrils are in a lower-density state compared with the high-density areas R1 are provided alternately.SELECTED DRAWING: Figure 3

A method for generating a recyclate from dry coating material includes providing an agglomerated solidified coating material, where the coating material has a binder in the form of fibrils which form aggregates. A recyclate is generated by introducing forces, especially shearing forces, into the coating material in such a way that the agglomerate is broken up and the aggregate-forming fibrils are retained.

Compounds usable in treating a metabolic disorder associated with phenylalanine aggregation (fibril formation) and methods of identifying same are provided. The compounds include morin hydrate and structural analogs thereof and / or are collectively represented by Formula with the variables being as defined in the specification and claims. The compounds alternatively include those presented in Table 1 and / or compounds capable of aligning with a pharmacophoric model as described in the specification and drawings herein. Methods of identifying compounds capable of interfering with phenylalanine aggregation are also provided.

Compounds comprising a rhodanine scaffold, compositions comprising same, method of using such compounds find compositions to inhibit tubulin-associated unit (tau) protein aggregation or alpha-synuclein (α-syn) protein aggregation in a subject having, or at risk for, tau protein aggregation or α-syn protein aggregation, respectively; and methods of using such compounds and compositions to inhibit islet amyloid polypeptide (LAPP) fibril formation and to detect LAPP fibrils.

IAPP peptides which inhibit the aggregation of human Islet Amyloid Polypeptide and their use in inhibiting amyloid fibril formation.

Compounds of formula (I), pharmaceutical compositions of formula (I), and methods of use of compounds of formula (I) in the inhibition of α-syn protein aggregation, tau protein aggregation, oligomer formation, and / or fibril formation in a subject having, or at risk for, said aggregation / formation.

Compounds useful in the treatment or prevention of diabetes and related conditions and in the prevention, inhibition or reversal of amylin-amyloid fiber formation, the prevention of Langerhans island (beta) cell death, the prevention or reversal of the conversion of soluble human amylin to insoluble human amylin, the prevention and inhibition or reversal of cytotoxic amylin fiber formation. The present invention relates to compounds of formula (I): (I).

To provide a polybutylene naphthalate resin composition for a transportation device having excellent heat resistance and low thermal conductivity in the thickness direction and a molded member using the same.SOLUTION: There is provided a polybutylene naphthalate resin composition for a transportation device which is a resin composition comprising (B) 35 to 65 pts.wt. of a glass fiber (B component) and (C) 10 to 35 pts.wt. of a polytetrafluoroethylene (C component) having no fibril-forming capability based on (A) 100 pts.wt. of a polybutylene naphthalate resin (A component), wherein the content of a resin other than A component is less than 1 pt.wt. and the content of a filler other than B component is less than 1 pt.wt..SELECTED DRAWING: None

The present invention relates to the inhibitory effect of QBP1 on hIAPP amyloid formation disrupting the initial stages of hIAPP fibrillogenesis and mitigating hIAPP- induced islet amyloidosis toxicity. The invention relates to the peptide QBP1, or composition comprising thereof, for use in the treatment and / or prevention of the diabetes, particularly type 2 diabetes.

Provided is a novel amyloid fibril formation method that makes it possible to form amyloid fibrils more easily than in the past. According to the present invention, an amyloid fibril formation method for forming amyloid fibrils from an amyloid fibril formation protein involves allowing a fluid that includes the amyloid fibril formation protein to flow into a fluid tube and forming the amyloid fibrils from the amyloid fibril formation protein by transporting the fluid using a means that gradually compresses the fluid tube in one direction to pressurize and depressurize the fluid and thereby move the fluid through the fluid tube.

The present invention provides a peptide capable of inhibiting and disintegrating bacterial biofilm / fibril formation. Particularly, the present invention provides a retro inverso peptide which can inhibit the biofilm formation as well as disintegrates the pre-formed biofilm of Staphylococcus aureus.

IAPP peptides which inhibit the aggregation of human Islet Amyloid Polypeptide and their use in inhibiting amyloid fibril formation.